Managing and treating diabetes presuppose the increased attention to glycemic control as one of the major ways to preserve the desired states of patients and guarantee a high quality of life (Cowart, 2020). Most of the relevant medicines presuppose that post-meal sugar levels can be lowered by stimulating the release of insulin (Qiao et al., 2017). The following article “Treatment outcomes and tolerability following initiation of GLP-1 receptor agonists among type 2 diabetes patients in primary care practices in Germany” considers the effects of an innovative drug, GLP-1 Receptor Agonists, outcomes associated with their use, and the possibility of its wide use as the central tool to improve the situation and attain better results among patients with diabetes.
GLP-1 Receptor Agonists
The glucagon-like peptide can be viewed as a new possible solution to patients with type 2 diabetes. The given hormone is secreted from gastrointestinal cells soon after the meal and helps to stimulate the secretion of insulin in a glucose-dependent manner (Qiao et al., 2017). This given mechanism is critical for helping patients with the diseases as it also suppresses the secretion of glucagon and manages appetite (McCarty et al., 2019). In such a way, for patients with the given condition, the use of GLP-1 receptor agonists can be a beneficial option helping to manage the disease and avoid deterioration of their states.
To prove the effectiveness of GLP-1RA in managing diabetes, the researchers involved patients from 323 primary care practices (Qiao et al., 2017). The major demand was type 2 diabetes and participation in GLP-1RA therapy to compare outcomes and conclude about the effectiveness of the method (Qiao et al., 2017). In general, 544 individuals with the outlined condition were engaged, 54% male with an average age of 57.9 (Qiao et al., 2017). The given number of patients helped to conclude about the effectiveness of the measure, opportunities for its use in the future, and its nature compared to other interventions used at the moment.
The researchers were focused on the evaluation of treatment effects in broad populations. It means that the race, gender, and social status of all participants were not taken into account. The only demand was having type 2 diabetes and using the desired pill (Qiao et al., 2017). Moreover, by evaluating the changes in patients’ vitals and main showings, the authors were able to collect data needed for concluding about the effects and opportunities for using the GLP-1RA. That is why the three follow-up periods were added. In general, the peculiarities of the sample meet the main goal of the research and help to conclude about the effectiveness of a particular treatment.
Effectiveness of the Treatment Tool
Speaking about the treatment tool regarding results acquired from the involved population, the authors admit multiple positive benefits associated with the implementation of GLP-1RA (Qiao et al., 2017). Better glycemic control is linked to the substance, meaning that other practitioners can also recommend its use in similar situations. Moreover, suppressing glucagon and managing appetite, GLP-1RA helps patients to feel better and avoid too high sugar levels. It has a positive effect on their states. It means that the nature of the proposed intervention and positive influences related to therapy transform it into a preferable option.
In such a way, the study focuses on using GLP-1RA therapy as a possible and innovative treatment for patients with type 2 diabetes. Considering the fact that improved glycemic control is one of the major goals for such individuals, the integration of the given medicine into real practice can help to attain better outcomes among risk groups (Qiao et al., 2017). Additionally, the participants of the study also experience the given intervention, meaning that it remains a safe and promising option.
Cowart, K. (2020). Oral Semaglutide: First-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy, 54(5), 478–485.
McCarty, D., Olenik, A., & McCarty, B. P. (2019). Efficacy and safety of basal insulin/GLP-1 receptor agonist used in combination for type 2 diabetes management. Journal of Pharmacy Practice, 32(6), 671–678.
Qiao, Q., Johnsson, K., Grandy, S., & Kostev, K. (2017). Treatment outcomes and tolerability following initiation of GLP-1 receptor agonists among type 2 diabetes patients in primary care practices in Germany. Journal of Diabetes Science and Technology, 11(2), 272–277.